Literature DB >> 7371697

Nomographic estimation of time to reach steady-state serum concentration during phenytoin therapy.

S Vozeh, F Follath.   

Abstract

The time to reach steady-state on phenytoin therapy depends on the dose and the pharmacokinetic parameter of the individual patient. A nomogram is presented to help the physician to decide whether a measured serum concentration of phenytoin can be regarded as being within 20% of the steady-state level. The nomogram is based on the pharmacokinetic parameters of phenytoin reported for adult patients.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7371697     DOI： 10.1007/bf00561674

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  8 in total

1.  Pharmacokinetic study of a patient with diphenylhydantoin toxicity.

Authors:  A J Atkinson; J M Shaw
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

2.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

3.  Time to reach steady state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1978-06

4.  Rate of phenytoin accumulation in man: a simulation study.

Authors:  T M Ludden; J P Allen; L W Schneider; S A Stavchansky
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

5.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

6.  Phenytoin: pharmacokinetics and bioavailability.

Authors:  R Gugler; C V Manion; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

7.  Diphenylhydantoin elimination kinetics in overdosed children.

Authors:  L K Garrettson; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

8.  Individualization of phenytoin dosage regimens.

Authors:  T M Ludden; J P Allen; W A Valutsky; A V Vicuna; J M Nappi; S F Hoffman; J E Wallace; D Lalka; J L McNay
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875
  8 in total
  4 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study.

Authors:  S Vozeh; T Uematsu; L Aarons; P Maitre; H Landolt; O Gratzl
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

Review 4.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.